An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-DFU on wound healing of diabetic neuropathic ulcer (DFU).

Trial Profile

An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-DFU on wound healing of diabetic neuropathic ulcer (DFU).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs APZ 2 (Primary)
  • Indications Diabetic foot ulcer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors RHEACELL
  • Most Recent Events

    • 11 Jun 2018 Planned End Date changed from 1 Apr 2019 to 1 Dec 2019.
    • 11 Jun 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Mar 2019.
    • 16 Oct 2017 Planned End Date changed from 24 Feb 2019 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top